Zejing Pharmaceutical announced that the company received the “Notice of Acceptance” approved and issued by the State Drug Administration, and the marketing application for a new self-developed injectable human thyroid-beta indication was accepted. This indication is for treatment of patients with differentiated thyroid cancer without distant metastases to remove residual thyroid tissue with radioactive iodine after total thyroidectomy or near-total thyroidectomy. This drug belongs to class 3.2 of therapeutic biological products. It is the first innovative product approved for accurate evaluation of differentiated thyroid cancer after surgery in China. After the application is accepted, it still needs to go through review, on-site inspection and approval. There is uncertainty about the time and results of obtaining drug registration approval, and this matter will not have a significant impact on the company's recent performance.

Zejing Pharmaceutical announced that the company received the “Notice of Acceptance” approved and issued by the State Drug Administration, and the marketing application for a new self-developed injectable human thyroid-beta indication was accepted. This indication is for treatment of patients with differentiated thyroid cancer without distant metastases to remove residual thyroid tissue with radioactive iodine after total thyroidectomy or near-total thyroidectomy. This drug belongs to class 3.2 of therapeutic biological products. It is the first innovative product approved for accurate evaluation of differentiated thyroid cancer after surgery in China. After the application is accepted, it still needs to go through review, on-site inspection and approval. There is uncertainty about the time and results of obtaining drug registration approval, and this matter will not have a significant impact on the company's recent performance.